BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 36331428)

  • 1. Tumor-Selective Activation of Toll-Like Receptor 7/8 Agonist Nano-Immunomodulator Generates Safe Anti-Tumor Immune Responses upon Systemic Administration.
    Hao Y; Li H; Ge X; Liu Y; Li X; Liu Y; Chen H; Zhang S; Zou J; Huang L; Zhao F; Kang D; De Geest BG; Zhang Z
    Angew Chem Int Ed Engl; 2022 Dec; 61(52):e202214992. PubMed ID: 36331428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toll-like receptor-targeted particles: A paradigm to manipulate the tumor microenvironment for cancer immunotherapy.
    Tran TH; Tran TTP; Truong DH; Nguyen HT; Pham TT; Yong CS; Kim JO
    Acta Biomater; 2019 Aug; 94():82-96. PubMed ID: 31129358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
    Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
    J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Masking of Synthetic Immunomodulator Evokes Antitumor Immunity With Reduced Immune Tolerance and Systemic Toxicity by Temporal Activity Recovery and Sustained Stimulation.
    Shin HS; Kim S; Jin SM; Yoo YJ; Heo JH; Lim YT
    Adv Mater; 2024 Mar; 36(9):e2309039. PubMed ID: 37903320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists.
    Rajagopal D; Paturel C; Morel Y; Uematsu S; Akira S; Diebold SS
    Blood; 2010 Mar; 115(10):1949-57. PubMed ID: 20065291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.
    Jasani B; Navabi H; Adams M
    Vaccine; 2009 May; 27(25-26):3401-4. PubMed ID: 19200817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pH-/Enzyme-Responsive Nanoparticle Selectively Targets Endosomal Toll-like Receptors to Potentiate Robust Cancer Vaccination.
    Xia H; Qin M; Wang Z; Wang Y; Chen B; Wan F; Tang M; Pan X; Yang Y; Liu J; Zhao R; Zhang Q; Wang Y
    Nano Lett; 2022 Apr; 22(7):2978-2987. PubMed ID: 35302770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses.
    Loré K; Betts MR; Brenchley JM; Kuruppu J; Khojasteh S; Perfetto S; Roederer M; Seder RA; Koup RA
    J Immunol; 2003 Oct; 171(8):4320-8. PubMed ID: 14530357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo cancer vaccination: Which dendritic cells to target and how?
    Chiang CL; Kandalaft LE
    Cancer Treat Rev; 2018 Dec; 71():88-101. PubMed ID: 30390423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies.
    Martinsen JT; Gunst JD; Højen JF; Tolstrup M; Søgaard OS
    Front Immunol; 2020; 11():1112. PubMed ID: 32595636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toll-Like Receptor Agonists as Adjuvants for Allergen Immunotherapy.
    Kirtland ME; Tsitoura DC; Durham SR; Shamji MH
    Front Immunol; 2020; 11():599083. PubMed ID: 33281825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
    Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of indoleamine 2,3-dioxygenase activity enhances the anti-tumour effects of a Toll-like receptor 7 agonist in an established cancer model.
    Ito H; Ando T; Arioka Y; Saito K; Seishima M
    Immunology; 2015 Apr; 144(4):621-30. PubMed ID: 25322876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delivery of TLR7 agonist to monocytes and dendritic cells by DCIR targeted liposomes induces robust production of anti-cancer cytokines.
    Klauber TCB; Laursen JM; Zucker D; Brix S; Jensen SS; Andresen TL
    Acta Biomater; 2017 Apr; 53():367-377. PubMed ID: 28153581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toll-like receptor 8 agonist nanoparticles mimic immunomodulating effects of the live BCG vaccine and enhance neonatal innate and adaptive immune responses.
    Dowling DJ; Scott EA; Scheid A; Bergelson I; Joshi S; Pietrasanta C; Brightman S; Sanchez-Schmitz G; Van Haren SD; Ninković J; Kats D; Guiducci C; de Titta A; Bonner DK; Hirosue S; Swartz MA; Hubbell JA; Levy O
    J Allergy Clin Immunol; 2017 Nov; 140(5):1339-1350. PubMed ID: 28343701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Innate immune responses after stimulation with Toll-like receptor agonists in ex vivo microglial cultures and an in vivo model using mice with reduced microglia.
    Carroll JA; Race B; Williams K; Striebel JF; Chesebro B
    J Neuroinflammation; 2021 Sep; 18(1):194. PubMed ID: 34488805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gold Nanoparticles Coimmobilized with Small Molecule Toll-Like Receptor 7 Ligand and α-Mannose as Adjuvants.
    Shinchi H; Yamaguchi T; Moroishi T; Yuki M; Wakao M; Cottam HB; Hayashi T; Carson DA; Suda Y
    Bioconjug Chem; 2019 Nov; 30(11):2811-2821. PubMed ID: 31560198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. pH-degradable imidazoquinoline-ligated nanogels for lymph node-focused immune activation.
    Nuhn L; Vanparijs N; De Beuckelaer A; Lybaert L; Verstraete G; Deswarte K; Lienenklaus S; Shukla NM; Salyer AC; Lambrecht BN; Grooten J; David SA; De Koker S; De Geest BG
    Proc Natl Acad Sci U S A; 2016 Jul; 113(29):8098-103. PubMed ID: 27382168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bacterial Protein Toll-Like-Receptor Agonists: A Novel Perspective on Vaccine Adjuvants.
    Kumar S; Sunagar R; Gosselin E
    Front Immunol; 2019; 10():1144. PubMed ID: 31191528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecule engineering strategy of toll-like receptor 7/8 agonists designed for potentiating immune stimuli activation.
    Gu L; Kong X; Li M; Chen R; Xu K; Li G; Qin Y; Wu L
    Chem Commun (Camb); 2024 May; 60(42):5474-5485. PubMed ID: 38712400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.